JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 37 No. 1 171-177
© 1996 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blaufox, M. D.
Right arrow Articles by Davis, B. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blaufox, M. D.
Right arrow Articles by Davis, B. R.

Cost Efficacy of the Diagnosis and Therapy of Renovascular Hypertension

M. Donald Blaufox, Michael L. Middleton, Josephine Bongiovanni and Barry R. Davis

Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York
University of Texas Health Science Center, Houston, Texas

Correspondence: For correspondence or reprints contact: M. Donald Blaufox, MD, PhD, Department of Nuclear Medicine, Albert Einstein College of Medicine, 1695A Eastchester Rd., Bronx, NY 10461.

ABSTRACT

Numerous competing diagnostic modalities and the lack of data about therapeutic benefit result in controversy concerning the identification and treatment of renovascular hypertension. Methods: Meta-analyses were used to examine the cost efficacy of renovascular hypertension diagnosis and treatment. Sensitivity, specificity and predictive value were calculated for captopril renography, Doppler, the captopril test and arteriography. Sensitivities and specificities were used to project cost per patient cured or improved for each modality. This was compared with the lifetime cost of medical therapy. Cost efficacy was calculated using a hypothetical population (1000 patients, a prevalency rate of 30% for renal artery stenosis, expected cure or improvement rate of 0.77 after angioplasty). Results: The sensitivity, specificity and positive predictive values were similar for all modalities except the captopril test, which had a significantly lower sensitivity. The specificity was similar for all procedures; Doppler was highest but was mitigated by a 17% technical failure rate. The cost per patient cured or improved is greatest for arteriography and lowest for the captopril test. The relationship between cost per patient cured and the number of patients diagnosed in the population was calculated (relative value = (1/cost) x number patients detected). The relative value of captopril renography and arteriography is similar. Doppler and the captopril test have the lowest relative value. If angioplasty reduces medication by three drugs, the savings is $5807 to $8046 per patient. Surgical therapy is not cost-effective. Conclusion: Screening for renovascular hypertension is not cost-effective at a prevalence less than 30%, but captopril renography is equally cost-effective as arteriography and obviates the need for an arteriogram in many patients.

Key Words: renovascular hypertension • captopril renography • arteriography • cost efficacy




This article has been cited by other articles:


Home page
RadiologyHome page
D. van Helvoort-Postulart, C. D. Dirksen, P. J. Nelemans, A. A. Kroon, A. G. H. Kessels, P. W. de Leeuw, G. B. C. Vasbinder, J. M. A. van Engelshoven, and M. G. M. Hunink
Renal Artery Stenosis: Cost-effectiveness of Diagnosis and Treatment
Radiology, August 1, 2007; 244(2): 505 - 513.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
J. P. Bolduc, V. L. Oliva, E. Therasse, M.-F. Giroux, L. Bouchard, P. Perreault, A. Cliche, and G. Soulez
Diagnosis and Treatment of Renovascular Hypertension: A Cost-Benefit Analysis
Am. J. Roentgenol., March 1, 2005; 184(3): 931 - 937.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
G. Picciotto, A. Sargiotto, M. Petrarulo, C. Rabbia, P. G. De Filippi, and D. Roccatello
Reliability of Captopril Renography in Patients Under Chronic Therapy with Angiotensin II (AT1) Receptor Antagonists
J. Nucl. Med., October 1, 2003; 44(10): 1574 - 1581.
[Abstract] [Full Text] [PDF]


Home page
RadioGraphicsHome page
S. D. Sarkar, D. N. Siegel, G. Soulez, and V. L. Oliva
Invited Commentary Authors' Response
RadioGraphics, September 1, 2000; 20(5): 1368 - 1372.
[Full Text] [PDF]


Home page
PERSPECT VASC SURG ENDOVASC THERHome page
K. A. Collins and R. J. Gusberg
Current Perspectives on the Role of Captopril Imaging in the Diagnosis of Renovascular Disease
Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 2000; 13(1): 43 - 69.
[Abstract] [PDF]


Home page
ANN INTERN MEDHome page
E. J. Fine and M. D. Blaufox
Prediction Rule for Renal Artery Stenosis
Ann Intern Med, August 3, 1999; 131(3): 227 - 228.
[Full Text] [PDF]


Home page
ANN INTERN MEDHome page
P. Krijnen, E. W. Steyerberg, and B. C. van Jaarsveld
Prediction Rule for Renal Artery Stenosis
Ann Intern Med, August 3, 1999; 131(3): 228 - 228.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1996 by the Society of Nuclear Medicine.